| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 644 | 2017 |
| Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer S Chan, N Davidson, E Juozaityte, F Erdkamp, A Pluzanska, N Azarnia, ... Annals of Oncology 15 (10), 1527-1534, 2004 | 219 | 2004 |
| Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short‐course radiotherapy or long‐term … T Latkauskas, H Pauzas, I Gineikiene, R Janciauskiene, E Juozaityte, ... Colorectal Disease 14 (3), 294-298, 2012 | 154 | 2012 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients A Inciura, A Simavicius, E Juozaityte, J Kurtinaitis, R Nadisauskiene, ... BMC cancer 6, 1-7, 2006 | 81 | 2006 |
| Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori … J Kupcinskas, T Wex, J Bornschein, M Selgrad, M Leja, E Juozaityte, ... BMC medical genetics 12, 1-9, 2011 | 79 | 2011 |
| Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo … D Miles, A Chan, G Romieu, L Dirix, J Cortes, X Pivot, P Tomczak, ... Cancer research 69 (24_Supplement), 41-41, 2009 | 60 | 2009 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study M Rudzianskiene, A Inciura, R Gerbutavicius, V Rudzianskas, A Macas, ... Strahlentherapie und Onkologie 193 (9), 742, 2017 | 49 | 2017 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 46 | 2021 |
| Impact of morphology and biology on the prognosis of patients with gliomas. I Gudinaviciene, D Pranys, E Juozaityte Medicina (Kaunas, Lithuania) 40 (2), 112-120, 2004 | 45 | 2004 |
| The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients E Korobeinikova, D Myrzaliyeva, R Ugenskiene, D Raulinaityte, ... BMC genetics 16, 1-11, 2015 | 41 | 2015 |
| Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy V Rudzianskas, A Inciura, E Juozaityte, M Rudzianskiene, R Kubilius, ... Acta Otorhinolaryngologica Italica 32 (5), 297, 2012 | 40 | 2012 |
| Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes S Liutkauskiene, S Grizas, K Jureniene, J Suipyte, A Statnickaite, ... BMC cancer 18, 1-9, 2018 | 38 | 2018 |
| Impact of arterial hypertension on doxorubicin-based chemotherapy-induced subclinical cardiac damage in breast cancer patients D Vaitiekus, G Muckiene, A Vaitiekiene, D Maciuliene, D Vaiciuliene, ... Cardiovascular Toxicology 20, 321-327, 2020 | 34 | 2020 |
| Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients S Liutkauskiene, R Janciauskiene, K Jureniene, S Grizas, R Malonyte, ... BMC cancer 15, 1-8, 2015 | 30 | 2015 |
| Comparison of implant quality between loose and intra-operatively linked iodine-125 seeds in prostate cancer brachytherapy L Jarusevicius, A Inciura, E Juozaityte, K Vaiciunas, A Vaitkus, ... Journal of radiation research 53 (3), 439-446, 2012 | 28 | 2012 |
| Krūties vėžys E Juozaitytė Lietuvos bendrosios praktikos gydytojas. Kaunas: Vitae Litera, 2009, t. 13 …, 2009 | 26 | 2009 |
| Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer A Inciura, V Atkocius, E Juozaityte, D Vaitkiene Journal of radiation research 51 (6), 675-681, 2010 | 24 | 2010 |
| Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study V Rudžianskas, A Inčiūra, S Vaitkus, E Padervinskis, M Rudžianskienė, ... Medicina 50 (2), 92-99, 2014 | 23 | 2014 |
